Cargando…

The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial

Objective: Schizophrenia, as one of the most severe psychiatric diseases, has a chronic and debilitating process. The majority of patients with schizophrenia do not respond adequately to treatment with common antipsychotic drugs. Therapeutic problems induced by drug side effects as well as undesired...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseini, Seyed Ahmad, Sepehrmanesh, Zahra, Gilasi, Hamidreza, Ghoraishi, Fatemeh Sadat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Psychiatry & Psychology Research Center, Tehran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422942/
https://www.ncbi.nlm.nih.gov/pubmed/37575608
http://dx.doi.org/10.18502/ijps.v18i3.13002
_version_ 1785089337372704768
author Hosseini, Seyed Ahmad
Sepehrmanesh, Zahra
Gilasi, Hamidreza
Ghoraishi, Fatemeh Sadat
author_facet Hosseini, Seyed Ahmad
Sepehrmanesh, Zahra
Gilasi, Hamidreza
Ghoraishi, Fatemeh Sadat
author_sort Hosseini, Seyed Ahmad
collection PubMed
description Objective: Schizophrenia, as one of the most severe psychiatric diseases, has a chronic and debilitating process. The majority of patients with schizophrenia do not respond adequately to treatment with common antipsychotic drugs. Therapeutic problems induced by drug side effects as well as undesired results are major challenging issues regarding this disease. This study aimed at evaluating the effect of memantine supplementation on the improvement of cognitive symptoms in patients with schizophrenia. Method : The present clinical trial was performed on 50 patients with acute schizophrenia who were admitted to Kargarnejad Psychiatric Hospital in Kashan in 2022 and who were diagnosed as schizophrenia cases at least three months ago. Patients were randomly divided into either the intervention group (n = 25) or the placebo group (n = 25). The intervention group received 5 mg of memantine per day for three months. The dose of memantine in this group was increased to the maximum of 20 mg per day. The placebo group received 1 mg of folic acid per day for three months. Moreover, an identical routine schizophrenia therapeutic regimen was administered to all patients. The effectiveness of memantine was evaluated using the Wechsler Adult Intelligence Scale (WAIS-III), which assessed cognitive ability in older adults over a 12-week follow-up period. Results: The WAIS-III score in the 12th week of the study was significantly different between the placebo and intervention groups (P = 0.004), such that the score of the memantine group was higher than that of the placebo group. No significant difference was observed between the two groups in terms of drug side effects. Conclusion: Memantine can be supplemented in the treatment of schizophrenia so as to improve the cognitive symptoms of this disorder. However, subsequent studies involving larger sample sizes and different doses seem to be necessary to provide more accurate results in this respect.
format Online
Article
Text
id pubmed-10422942
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Psychiatry & Psychology Research Center, Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-104229422023-08-13 The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial Hosseini, Seyed Ahmad Sepehrmanesh, Zahra Gilasi, Hamidreza Ghoraishi, Fatemeh Sadat Iran J Psychiatry Original Article Objective: Schizophrenia, as one of the most severe psychiatric diseases, has a chronic and debilitating process. The majority of patients with schizophrenia do not respond adequately to treatment with common antipsychotic drugs. Therapeutic problems induced by drug side effects as well as undesired results are major challenging issues regarding this disease. This study aimed at evaluating the effect of memantine supplementation on the improvement of cognitive symptoms in patients with schizophrenia. Method : The present clinical trial was performed on 50 patients with acute schizophrenia who were admitted to Kargarnejad Psychiatric Hospital in Kashan in 2022 and who were diagnosed as schizophrenia cases at least three months ago. Patients were randomly divided into either the intervention group (n = 25) or the placebo group (n = 25). The intervention group received 5 mg of memantine per day for three months. The dose of memantine in this group was increased to the maximum of 20 mg per day. The placebo group received 1 mg of folic acid per day for three months. Moreover, an identical routine schizophrenia therapeutic regimen was administered to all patients. The effectiveness of memantine was evaluated using the Wechsler Adult Intelligence Scale (WAIS-III), which assessed cognitive ability in older adults over a 12-week follow-up period. Results: The WAIS-III score in the 12th week of the study was significantly different between the placebo and intervention groups (P = 0.004), such that the score of the memantine group was higher than that of the placebo group. No significant difference was observed between the two groups in terms of drug side effects. Conclusion: Memantine can be supplemented in the treatment of schizophrenia so as to improve the cognitive symptoms of this disorder. However, subsequent studies involving larger sample sizes and different doses seem to be necessary to provide more accurate results in this respect. Psychiatry & Psychology Research Center, Tehran University of Medical Sciences 2023-07 /pmc/articles/PMC10422942/ /pubmed/37575608 http://dx.doi.org/10.18502/ijps.v18i3.13002 Text en Copyright © 2023 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Hosseini, Seyed Ahmad
Sepehrmanesh, Zahra
Gilasi, Hamidreza
Ghoraishi, Fatemeh Sadat
The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
title The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
title_full The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
title_fullStr The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
title_full_unstemmed The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
title_short The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
title_sort effect of memantine versus folic acid on cognitive impairment in patients with schizophrenia: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422942/
https://www.ncbi.nlm.nih.gov/pubmed/37575608
http://dx.doi.org/10.18502/ijps.v18i3.13002
work_keys_str_mv AT hosseiniseyedahmad theeffectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT sepehrmaneshzahra theeffectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT gilasihamidreza theeffectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT ghoraishifatemehsadat theeffectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT hosseiniseyedahmad effectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT sepehrmaneshzahra effectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT gilasihamidreza effectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial
AT ghoraishifatemehsadat effectofmemantineversusfolicacidoncognitiveimpairmentinpatientswithschizophreniaarandomizedclinicaltrial